Neuroendocrine Tumors

Delivered tumor dose for neuroendocrine tumors increased by combining I-131-MIBG with Y-90-DOTATOC

Published in Cancer Weekly, June 19th, 2006

Delivered tumor dose for radiotherapy of neuorendocrine tumors was increased by combining I-131-Metaiodobenzylguanidine (I-131-MIBG) with Y-90-DOTA-D-Phe1-Tyr3-octreotide (Y-90-DOTATOC).

"I-131-MIBG and Y-90-DOTATOC have been used as radiotherapeutic agents for treating neuroenclocrine tumors. The tumor dose delivered by these agents is often insufficient to control or cure the disease," researchers in the United States reported.

"However, these 2 agents used together could potentially increase tumor dose without exceeding the critical organ dose because the dose-limiting tissues are different," explained M.T. Madsen and colleagues, University of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry